TerminatedPHASE1, PHASE2NCT00346983
Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics
Studying Cystoid macular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Oliver D. Schein, MD, MPH, MBAJohns Hopkins University
- Intervention
- Pegaptanib sodium(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2007
Study locations (1)
- The Johns Hopkins Hospital, Baltimore, Maryland, United States
Collaborators
Eyetech Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00346983 on ClinicalTrials.govOther trials for Cystoid macular dystrophy
Additional recruiting or active studies for the same condition.